(Q38152289)

29 August 2017

title

Circulating biomarkers in patients with heart failure and preserved ejection fraction (English)

1 reference

29 August 2017

0 references

0 references

1 reference

2

Simon de Denus

1 reference

29 August 2017

3

Jean-Lucien Rouleau

1 reference

29 August 2017

Eileen O'Meara

1

1 reference

29 August 2017

Akshay Desai

series ordinal

4

1 reference

29 August 2017

publication date

1 December 2013

1 reference

Current heart failure reports

29 August 2017

published in

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

350-358

1 reference

Heart failure with preserved systolic function. A different natural history?

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Heart failure with a normal ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Systolic and diastolic heart failure in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Trends in prevalence and outcome of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Outcome of heart failure with preserved ejection fraction in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Biomarker-guided therapies in heart failure: a forum for unified strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Biochemical assessment of myocardial fibrosis in hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Circulating biomarkers of collagen metabolism in cardiac diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

ECM remodeling in hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Cystatin C concentration as a predictor of systolic and diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Albuminuria in chronic heart failure: prevalence and prognostic importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Troponin elevation in heart failure prevalence, mechanisms, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Identification of serum soluble ST2 receptor as a novel heart failure biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

ST2 as a cardiovascular risk biomarker: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non ST-Elevation Acute Coronary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Filling Pressures and Collagen Metabolism in Hypertensive Patients With Heart Failure and Normal Ejection Fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Systolic and Diastolic Heart Failure Are Overlapping Phenotypes Within the Heart Failure Spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-013-0160-X

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease

21 January 2018

1 reference

12 December 2020

B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy

1 reference

12 December 2020

Elevated B-type natriuretic peptide level: use with caution in patients with multiple co-morbidities and presenting with dyspnea

1 reference

12 December 2020

Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations

1 reference

12 December 2020

Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure

1 reference

12 December 2020

Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study)

1 reference

12 December 2020

Galectin-3: a novel blood test for the evaluation and management of patients with heart failure

1 reference

12 December 2020

Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism

1 reference

12 December 2020

ST2 protein in heart disease: from discovery to mechanisms and prognostic value

1 reference

12 December 2020

Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial

1 reference

12 December 2020

Serum Carboxy-Terminal Propeptide of Procollagen Type I Is a Marker of Myocardial Fibrosis in Hypertensive Heart Disease

1 reference

12 December 2020

Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy

1 reference

12 December 2020

Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension

1 reference

12 December 2020

Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction

1 reference

12 December 2020

Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation

1 reference

12 December 2020

Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction

1 reference

12 December 2020

Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)

1 reference

12 December 2020

Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22

1 reference

12 December 2020

Impact of arterial load and loading sequence on left ventricular tissue velocities in humans

1 reference

12 December 2020

Biological determinants of aldosterone-induced cardiac fibrosis in rats.

1 reference

12 December 2020

Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis

1 reference

12 December 2020

Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations

1 reference

12 December 2020

Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

1 reference

12 December 2020

Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle

1 reference

12 December 2020

10.1007/S11897-013-0160-X

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1049627039

0 references

1 reference